What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Immune system
Gerald J. Gleich mainly focuses on Immunology, Eosinophil, Major basic protein, Eosinophil Granule Proteins and Internal medicine.
His Eosinophil degranulation, Eosinophilia, Interleukin 5, Hypereosinophilic syndrome and Immunoglobulin E study are his primary interests in Immunology.
His Eosinophil study combines topics in areas such as Molecular biology, Histamine and Pathology.
Gerald J. Gleich has researched Major basic protein in several fields, including Muscarinic acetylcholine receptor, Muscarinic acetylcholine receptor M2, Biochemistry, Granule and Arginine.
His Eosinophil Granule Proteins study combines topics from a wide range of disciplines, such as Blood proteins, Epithelium and Guinea pig.
His Internal medicine study integrates concerns from other disciplines, such as Gastroenterology and Endocrinology.
His most cited work include:
- A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica (947 citations)
- Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements. (859 citations)
- Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. (786 citations)
What are the main themes of his work throughout his whole career to date?
Gerald J. Gleich focuses on Immunology, Eosinophil, Major basic protein, Pathology and Internal medicine.
His research in Immunoglobulin E, Eosinophilia, Allergy, Antibody and Interleukin 5 are components of Immunology.
His Immunoglobulin E research is multidisciplinary, incorporating perspectives in Ragweed and Antigen.
His Eosinophil research integrates issues from Molecular biology and Degranulation.
His Major basic protein research includes elements of Biochemistry, Granule, Histamine and Cell biology.
His studies in Internal medicine integrate themes in fields like Gastroenterology and Endocrinology.
He most often published in these fields:
- Immunology (54.87%)
- Eosinophil (42.41%)
- Major basic protein (27.51%)
What were the highlights of his more recent work (between 2009-2021)?
- Immunology (54.87%)
- Eosinophil (42.41%)
- Eosinophilic esophagitis (4.58%)
In recent papers he was focusing on the following fields of study:
His primary areas of study are Immunology, Eosinophil, Eosinophilic esophagitis, Internal medicine and Pathology.
His study in Immunology concentrates on Hypereosinophilic syndrome, Eosinophilia, Immunoglobulin E, Allergy and Interleukin 5.
He has included themes like Peripheral blood mononuclear cell and Pharmacology in his Eosinophil study.
His Internal medicine research focuses on subjects like Gastroenterology, which are linked to Surgery.
His biological study spans a wide range of topics, including Echogenicity and Ultrasound.
His research investigates the link between Eosinophil peroxidase and topics such as Eosinophil cationic protein that cross with problems in Cell biology.
Between 2009 and 2021, his most popular works were:
- Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema (390 citations)
- Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. (348 citations)
- Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis (306 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Immune system
His primary areas of investigation include Immunology, Eosinophil, Eosinophilic esophagitis, Eosinophilia and Hypereosinophilic syndrome.
The various areas that Gerald J. Gleich examines in his Immunology study include Clinical trial and Family medicine.
Major basic protein is the focus of his Eosinophil research.
His work deals with themes such as Eosinophilic endomyocardial disease, Protein subcellular localization prediction, Ulcerative colitis and Immunohistochemistry, which intersect with Major basic protein.
His research in Eosinophilic esophagitis intersects with topics in Gastroenterology, Omalizumab and Esophagus.
As a part of the same scientific study, Gerald J. Gleich usually deals with the Hypereosinophilic syndrome, concentrating on Mepolizumab and frequently concerns with Prednisone.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
